Statins May Lower HF Risk in BC Patients on Anthracycline Chemotherapy
Anthracyclines and trastuzumab, two treatments for the management of early breast cancer (EBC), are associated with cardiotoxicity. This adverse effect can contribute to cardiovascular death from heart failure (HF) among elderly EBC survivors, and interventions to reduce the adverse cardiovascular effect are greatly needed. Read more.

Assessing the Efficacy and Safety of PARP Inhibitors in Breast Cancer
BRCA gene mutations augment the risk of developing breast cancer (BC), with the BRCA1 mutation increasing this risk by 50% to 65% and the BRCA2 mutation raising this risk by 40% to 57% by the time a woman is age 70 years. A systematic review and meta-analysis was conducted to assess the efficacy and safety of PARP inhibitors in BC compared with chemotherapy. Read more.

Choosing Between an Aromatase Inhibitor or Tamoxifen in Perimenopausal Patients
The choice of endocrine treatment for estrogen receptor-positive perimenopausal patients has been met with controversy in recent years. Tamoxifen has traditionally been preferred over the use of aromatase inhibitors (AIs) in this group because AIs only decrease extra-ovarian estrogen production. Read more.